OpenAI Bets $252M on Mind-Reading Ultrasound. The BCI Gold Rush Just Went Vertical.

Merge Labs emerges from stealth this week with quarter-billion backing from OpenAI. Synchron marks five years with a brain implant and is still finding new uses for it. China's Gestala wants to skip the surgery entirely. Japan just approved the world's first treatment made from reprogrammed human cells. And the scientist who gene-edited babies says he wants to do it again. The brain is no longer frontier territory - it's a market.

The brain-computer interface field spent a decade being interesting in a safely theoretical way. Researchers published papers. DARPA handed out grants. Elon Musk made headlines. But in the second week of March 2026, something shifted. In the span of 72 hours, multiple signals fired simultaneously: a $252 million stealth startup backed by OpenAI went public, Japan's government approved a landmark cell therapy built from reprogrammed human cells, and a Chinese company announced it wants to read your brain without cutting your skull open.

Meanwhile, the man who went to prison for gene-editing babies told the world he plans to do it again - this time targeting Alzheimer's. And a patient in Australia who has had a Synchron brain implant for five years keeps finding new things it can do.

These stories are all related. The underlying current running through all of them is the same: the human body, specifically its most protected and mysterious organ, is now a viable technology platform. The question is who gets to build on it, and what the rules will be.

Merge Labs: OpenAI's Brain Bet

Merge Labs emerged from stealth this week with $252 million in funding from OpenAI and a cluster of other investors. The company, founded by former OpenAI researchers, is building a brain-computer interface system based on focused ultrasound - a non-invasive technique that uses high-frequency sound waves directed through the skull to stimulate or read neural activity.

The approach is distinct from both Neuralink's implanted electrodes and Synchron's endovascular stent. You do not need surgery. You do not need a catheter snaked through your jugular. You put on a device that looks roughly like a pair of large headphones, and the focused ultrasound array targets specific regions of your cortex with millimeter precision.

The science behind this is well-established in research settings. Transcranial focused ultrasound (tFUS) has been used in labs for over a decade to modulate brain activity. The breakthrough Merge Labs claims is miniaturization and real-time closed-loop feedback - meaning the system can both read and write to the brain simultaneously, adjusting its output based on what it detects. Think of it as two-way communication rather than a one-way loudspeaker.

What does OpenAI want with a brain-reading company? The obvious answer is the one that makes AI researchers uncomfortable to say out loud: the ultimate high-bandwidth input device. Current human-computer interaction is bottlenecked at keyboards, touchscreens, and voice commands. All of them are slow. A direct neural interface theoretically lets thought move at the speed of intent rather than the speed of fingers. If you are building the AI systems that will run the next generation of human productivity, removing that bottleneck is strategically critical.

"The interface layer between humans and AI is the most important unsolved problem in technology. Everything else we build is constrained by how fast and accurately humans can express their intentions." - Common framing in the BCI investment community, echoed across multiple recent funding announcements

There is also a less flattering read. OpenAI is under competitive pressure from multiple directions - Google, Anthropic, Meta, Chinese labs. If AI capability improvements start to plateau as many researchers predict they eventually will, the next competitive moat could be integration depth. A company that owns both the AI and the neural interface that connects it to human thought has a fundamentally different kind of lock-in than a company that merely has a better chatbot.

Merge Labs is not alone. The company enters a field that already has Neuralink (implanted chips, human trials ongoing), Synchron (endovascular stent-electrode, FDA cleared), Kernel (non-invasive neuroimaging), and now Gestala from China. The non-invasive segment is particularly crowded because it avoids the regulatory nightmare of cutting open skulls. But "non-invasive" in the ultrasound context still carries risks that are incompletely understood - particularly around cumulative thermal effects on tissue from repeated or prolonged use.

Five Years Inside Rodney Gorham's Head

While Merge Labs is betting on the future, Rodney Gorham is already living in it. He is the longest-running user of a Synchron Stentrode - a flexible mesh electrode array that is delivered into the brain's motor cortex via a catheter inserted through the jugular vein. No open skull surgery. The stent deploys and attaches to the blood vessel wall, sitting adjacent to the cortex and picking up electrical signals from motor neurons.

Gorham, who has motor neuron disease (ALS-adjacent), got his device five years ago in Australia as part of Synchron's first-in-human trial. According to WIRED's reporting this week, he is still finding new applications for it. He uses it to control a computer, communicate, and navigate daily life. The device has not degraded in performance over five years - something that was genuinely uncertain when the trial began.

This matters more than it sounds. One of the fundamental engineering challenges in implanted BCIs is the brain's immune response to foreign objects. The brain treats implanted electrodes like an infection - it encapsulates them in glial scar tissue, which progressively insulates the electrode and degrades signal quality. This is why many brain implants work brilliantly for the first year and then slowly go quiet. Synchron's endovascular approach sidesteps the worst of this by placing the electrode inside a blood vessel rather than the brain tissue itself, reducing direct contact with neurons that trigger the inflammatory cascade.

Five years of stable performance in a single patient is not a clinical trial result. It is one data point. But it is a data point that Synchron desperately needed. The company has FDA Breakthrough Device designation and has been running US trials at sites including Mount Sinai and Carnegie Mellon. Five years of Gorham living with his device gives those sites a reassuring longitudinal anchor.

What Gorham's case also demonstrates is the gap between what the neurotech industry promises and what it actually delivers in the near term. Nobody is using a Stentrode to control a robotic arm at superhuman speed or to upload memories. They are using it to type on a screen. Slowly, but independently. For someone with ALS who has lost voluntary motor control, that is genuinely life-changing. But it is not the transhumanist leap that gets investment decks past $100 million. The hype and the reality exist in different time frames, and the industry needs to be honest about that gap to maintain public trust through the longer development arc.

Gestala: China's No-Surgery Brain Reader

China's Gestala announced its technology this week with a pitch that sounds almost too convenient: a non-invasive BCI using focused ultrasound that does not require any physical attachment to the head. The company is positioning itself against Neuralink with what amounts to a completely different premise - not better implants, but no implants at all.

The technical details Gestala has released publicly are limited. What they have described involves a focused ultrasound transducer array that can be positioned near the skull without contact, using beamforming algorithms to target specific cortical regions. The company claims it can read motor intentions with enough accuracy to control external devices.

Skepticism is warranted here, but not dismissal. Transcranial focused ultrasound used for reading neural signals (as opposed to stimulation) is genuinely difficult. The skull attenuates and scatters ultrasound, and extracting fine-grained neural signals from that noisy environment without skull contact would represent a significant technical advance. Gestala has not published peer-reviewed data yet. Until it does, the claim sits somewhere between ambitious engineering and vaporware.

What is not in doubt is the strategic context. China has been explicitly building its BCI industry as a national technology priority. The Ministry of Science and Technology has funded research programs at multiple universities. Several Chinese BCI companies have already conducted first-in-human trials. The broader pattern - where a Chinese company announces a non-invasive alternative to a U.S. surgical technology - echoes what happened in EV batteries, drones, and solar panels. The question is whether BCI follows the same trajectory from "interesting Chinese startup" to "market-defining competitor" in a compressed timeline.

For Merge Labs, Synchron, and Neuralink, Gestala is worth monitoring precisely because the non-invasive segment is where consumer adoption happens. Medical BCIs for paralyzed patients can justify the surgery. Consumer BCIs for typing or gaming or emotional monitoring cannot. If Gestala's approach works even at 60% of the fidelity of an implanted device, the addressable market comparison is not close.

Japan's World First: Reprogrammed Cells as Medicine

The brain is not the only frontier this week. Japan's health regulator approved what WIRED describes as the world's first treatment made with reprogrammed human cells - a milestone that has been 18 years in the making.

The technology is induced pluripotent stem cells, or iPSCs. Discovered by Shinya Yamanaka in 2006, iPSCs are created by taking ordinary adult cells - typically skin or blood cells - and reprogramming them back to a stem-cell-like state by introducing a set of transcription factors. From there, they can theoretically be differentiated into any cell type in the body. Heart muscle. Retinal tissue. Neurons. Yamanaka won the Nobel Prize in Physiology or Medicine in 2012 for this work.

The reason it has taken 18 years to get from Nobel Prize to first approved treatment is worth understanding. iPSCs created from a patient's own cells solve the immune rejection problem that plagued earlier stem cell therapies - but the reprogramming process itself introduces risks. The transcription factors used to reprogram cells include some that are associated with cancer development. Early iPSC methods introduced permanent genetic changes using viral vectors, raising safety flags. Newer methods use temporary RNA or protein delivery to avoid permanent genomic integration, and years of safety data have been required to satisfy regulators.

The specific treatment Japan approved has not been named in early reports, but the significance is regulatory rather than just scientific. Japan has historically been more willing than the U.S. FDA or European EMA to grant conditional approval to regenerative medicine therapies under its SAKIGAKE designation - a fast-track for innovative treatments. The world's first approved iPSC treatment coming from Japan rather than the U.S. or Europe is partly a result of that regulatory philosophy.

The second-order effect to watch: iPSC approvals create a reference point for regulators globally. The FDA, which has been cautious about cell therapy approvals despite a pipeline full of clinical trials, will face pressure to explain why it has not cleared comparable treatments. Japanese approval also gives pharmaceutical companies a proof-of-concept market where they can refine manufacturing processes and gather real-world safety data - which then strengthens regulatory dossiers in other jurisdictions.

For neuroscience specifically, iPSC-derived neurons are of particular interest for treating conditions like Parkinson's disease, where the dopaminergic neurons of the substantia nigra degenerate. If you can replace lost neurons with iPSC-derived ones, you are potentially treating the disease rather than managing symptoms. That is still years away. But Japan's approval this week cleared a philosophical and regulatory hurdle that matters.

He Jiankui Wants to Edit Brains Next

The most provocative element of this week's neurotech news cycle has nothing to do with ultrasound or venture capital. He Jiankui, the Chinese scientist who created the world's first gene-edited babies in 2018 - twins with a deleted CCR5 gene intended to confer HIV resistance - and then served three years in a Chinese prison for it, has announced he wants to do it again.

This time, his target is Alzheimer's disease. He has told interviewers he is planning clinical work and believes the Silicon Valley response to gene editing represents, in his framing, a "Nazi eugenic experiment." His positioning is as a researcher pursuing medical necessity rather than enhancement - though the distinction between those categories has never been as clean as proponents suggest.

His return is notable for several reasons that go beyond the headline controversy. First: he is legally permitted to conduct research in China, where he was convicted under regulations that were themselves somewhat improvised after his experiment. The regulatory landscape for germline gene editing in China has evolved since 2018 but remains more permissive in certain areas than U.S. or European frameworks. Second: the technology has advanced dramatically. CRISPR-Cas9, which He used in 2018, has been supplanted by base editing and prime editing - techniques that make more precise, reversible changes with fewer off-target effects. Third: Alzheimer's is a target with enormous public sympathy. The political calculus for regulatory tolerance is different when the patient population is elderly rather than embryonic.

The specific genetic target He has discussed for Alzheimer's is the APOE4 allele - the most significant known genetic risk factor for late-onset Alzheimer's, roughly tripling risk in heterozygous carriers and increasing it tenfold in those with two copies. Editing embryos to remove APOE4 would theoretically reduce Alzheimer's risk. The catch is that APOE4, like most common genetic variants, is not purely detrimental - it appears to confer some protection against certain infections and may have other pleiotropic effects that researchers do not fully understand yet. Editing it out in all embryos based on current knowledge would be making a permanent, multi-generational bet on incomplete science.

"He went to prison for gene-editing babies. Now he's planning to do it again." - WIRED Science desk, March 2026

The neurotech community's reaction has been muted, which is itself telling. Three years ago, He's announcement would have generated outrage. Today it generates analysis. That shift in tone reflects how much the field's norms have moved. The Overton window for body modification, neural intervention, and genetic alteration has been pulled open by a decade of venture capital, celebrity advocacy, and incremental regulatory approvals. He Jiankui is extreme. But he is operating on a spectrum that now has many more participants than it did in 2018.

GPS Attacks Near Iran: The Invisible Electronic Battlefield

Separate from the neurotech story, but essential context for the week's tech coverage: WIRED reported that GPS attacks near Iran have been causing widespread disruption to civilian delivery apps, navigation systems, and mapping services across the region.

The phenomenon is GPS spoofing - not jamming (which simply blocks the signal) but feeding false coordinates to receivers, causing them to believe they are somewhere they are not. Spoofing is significantly more technically demanding than jamming but also significantly more useful as a military tool. A jammed drone knows its navigation is broken. A spoofed drone thinks it knows exactly where it is - just incorrectly.

The disruptions WIRED described include delivery apps glitching to wrong locations, navigation routes changing abruptly mid-journey, and aviation warnings in multiple Gulf states. The electronic warfare activity is tied to the ongoing U.S.-Iran conflict, with both sides using GPS manipulation as part of their operational toolkit. Iran has a documented history of GPS spoofing going back to at least 2011, when Iranian military claimed to have captured a U.S. RQ-170 Sentinel drone using a spoofing attack - a claim that remains disputed but not definitively disproven.

The civilian impact is the underreported angle. Military GPS spoofing does not discriminate between military receivers and the billions of civilian devices that rely on the same signals. Every smartphone, delivery vehicle, emergency service, and commercial aircraft in the region is affected. The mapping disruptions create cascading effects: logistics networks go unreliable, emergency response slows, and the information environment degrades in ways that benefit whoever controls the spoofing apparatus.

The long-term implication is significant for the tech industry. GPS has become so foundational that developers rarely think about its failure modes. Autonomous vehicle systems, drone delivery networks, precision agriculture, and smart city infrastructure all sit on a foundation that can be undermined by adversarial electronic warfare. The Iran conflict is demonstrating, in real time, how fragile that foundation is when someone decides to attack it. Resilience engineering for GPS-dependent systems - multi-constellation navigation, inertial backup, blockchain-verified coordinate validation - is about to become a lot more commercially interesting.

The AI Coding Mess at Amazon: When Bots Break the Cloud

Amazon had a quiet but significant internal governance moment this week that deserves more attention than it received. According to the Financial Times, Amazon eCommerce SVP Dave Treadwell called an all-hands meeting after recent AWS outages were linked to errors introduced by AI coding agents. The response: junior and mid-level engineers will now need sign-off from senior engineers on any AI-assisted code changes.

This is one of the first documented cases of a major tech company visibly pulling back on AI coding agent autonomy after production incidents. The pattern is exactly what safety researchers have been warning about: AI coding assistants that are capable enough to make confident, plausible-looking changes to complex systems, but not capable enough to understand the full consequences of those changes at system scale.

AWS outages are not minor events. AWS infrastructure runs a substantial fraction of the global internet. An outage at the wrong time, in the wrong services, can cascade into widespread disruption of unrelated companies' operations. The fact that AI-assisted code changes are implicated - even partially - in AWS downtime events is a signal the industry needs to take seriously.

The second-order effect: Amazon's internal policy change is going to influence how other enterprises think about AI coding governance. When the company that owns the cloud infrastructure underlying so much of the internet decides it needs more human oversight on AI-generated code, that is a data point that enterprise CISOs and CTOs will cite in their own internal debates about AI coding tool deployment. Expect to see "senior engineer sign-off" clauses appearing in AI governance frameworks across financial services, healthcare, and critical infrastructure operators over the coming months.

The BCI revolution and the AI coding governance story are more connected than they appear. Both are about the same fundamental question: where is the appropriate boundary for automated systems making consequential decisions with limited human review? In coding, Amazon just moved that boundary back toward more oversight after it got burned. In brain interfaces, the industry is still in the phase of pushing the boundary forward - exciting enough that the risk calculus feels favorable. The sobering historical pattern is that the boundary-push phase always ends. The only question is whether it ends on someone's terms, or reality's.

What the BCI Gold Rush Gets Wrong

The week's neurotech news is genuinely exciting. $252 million into a non-invasive BCI startup is real money with real intent behind it. Japan's iPSC approval is a 18-year scientific journey reaching a tangible clinical milestone. Gorham's five years with a working brain implant is proof that the technology can work stably in a human being over a meaningful time horizon.

But the industry has a communication problem that the gold rush dynamic is making worse. Every funding announcement is accompanied by the same language: revolutionary, transformative, the future of human-computer interaction. The implicit promise is always the science-fiction version - full-bandwidth neural communication, memory augmentation, the merger of human and artificial intelligence. The actual near-term product is usually: a paralyzed person can type faster than they could with eye-tracking technology.

That gap matters because it shapes public expectations in ways that create backlash cycles. When the first generation of consumer BCI products arrives and it turns out they can read basic motor intentions or detect a handful of emotional states rather than stream consciousness to the cloud, the narrative will shift from "revolutionary" to "overhyped." That backlash will arrive at the same time that the harder, more interesting applications are just beginning to be feasible - exactly the wrong moment for public skepticism to peak.

The neurotech industry would benefit from being more like Gorham: honest about what the technology does today, enthusiastic about where it is headed, and clear about the timeline between those two points. Five years of stable brain-computer connection that lets a person with ALS live more independently is worth being proud of on its own terms. It does not need to be dressed up as something it is not.

The week's convergence of announcements - Merge Labs, Japan, Gestala, Gorham, He Jiankui's return - suggests that neurotech is no longer a niche waiting for its moment. The investment, the regulatory approvals, the improving technology, and the competition from China are all arriving simultaneously. That is what a gold rush looks like from the inside. It is loud, fast, and full of people making claims that outrun the evidence. The ones who survive it will be the ones who were right about the underlying resource - and patient enough to extract it correctly.